Early last month, a top contracting officer at a U S agency charged with accelerating the development of drugs to fight the COVID-19 pandemic got a request that made him feel uneasy Senior Trump administration officials had asked him to rapidly approve funding that would help a small pharmaceutical firm further develop a still-experimental drug being considered to treat COVID-19 The federal outlay could have ultimately amounted to $300 million or more But the contracting officer pushed back, according to a 13 April email obtained by ScienceInsider “We are uncomfortable with rushing forward” on the directive, Joffrey Benford wrote, calling it “impossible due to acquisition processes and procedures that are required for the size of this acquisition ”